Form 4: Rani Therapeutics Director Boosts Stake with $1.26M Share Purchase

Mir A. Imran, a Director and 10% owner of Rani Therapeutics Holdings, Inc., acquired over 2 million Class A Common Stock shares and warrants in a private placement.

Summary

• Mir A. Imran, a Director and 10% owner of Rani Therapeutics Holdings, Inc. (RANI), purchased 2,083,334 shares of Class A Common Stock at a price of $0.605 per share on October 23, 2025.
• The total value of the Class A Common Stock acquired directly by Mr. Imran in this transaction is approximately $1,260,000.
• Concurrently, Mr. Imran also acquired 2,083,334 warrants to purchase Class A Common Stock, with an exercise price of $0.48 per share.
• The shares were purchased in a Private Investment in Public Equity (PIPE) offering conducted by the Issuer.
• Following this transaction, Mr. Imran directly holds 2,083,334 shares of Class A Common Stock and 2,083,334 warrants.
• Indirect beneficial ownership includes 74,139 shares of Class A Common Stock and 22,660,053 shares of Class B Common Stock through entities such as InCube Ventures II, L.P., InCube Labs, L.L.C., and Rani Investment Corp., where Mr. Imran is a General Partner or wholly owns.

Sentiment

Score: 8

Explanation: The significant purchase of shares and warrants by a Director and 10% owner in a PIPE offering indicates strong insider confidence and a positive outlook on the company's valuation and future prospects.

Positives

• A Director and 10% owner made a significant personal investment, acquiring over $1.26 million in Class A Common Stock, signaling strong insider confidence in the company's future.
• The purchase was part of a PIPE offering, which can strengthen the company's capital structure.

Risks

• The warrants acquired are exercisable only upon stockholder approval, introducing a contingency for their value realization.
• The reporting person disclaims beneficial ownership of indirectly held securities except to the extent of his pecuniary interest therein, which may limit the direct alignment of interests for those specific shares.

Future Outlook

The warrants acquired will be exercisable upon obtaining stockholder approval and will have a term of exercise equal to five years from the date of such approval.

Industry Context

N/A

Related Party Transactions

• The reporting person holds indirect beneficial ownership of Class A and Class B Common Stock through entities where he is a General Partner (InCube Ventures II, L.P., Rani Investment Corp.) or wholly owns (InCube Labs, L.L.C.).

Stakeholder Impact

• Shareholders may view the significant insider purchase as a positive signal of management's belief in the company's value.
• The PIPE offering provides capital to the company, potentially strengthening its financial position.

Next Steps

• Obtain stockholder approval for the exercisability of the warrants.

Key Dates

Recommendation

The substantial investment by a Director and 10% owner, Mir A. Imran, through a direct purchase of over $1.26 million in Class A Common Stock and an equal number of warrants in a PIPE offering, signals strong insider confidence. Such a significant personal stake, especially from a key figure, often precedes positive developments or indicates a belief that the stock is undervalued. This insider buying suggests a favorable outlook from those closest to the company's operations and strategy, making it an attractive signal for potential investors.

Keywords

Rani Therapeutics, RANI, Mir A Imran, Insider Trading, Form 4, Share Purchase, Warrants, PIPE Offering, Director, 10% Owner, Equity Acquisition